Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Authors: Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer, Stanley Lipkowitz, Christina M. Annunziata, Maria J. Merino, Elizabeth M. Swisher, Maria I. Harrell, Jane B. Trepel, Min-Jung Lee, Mohammadhadi Bagheri, Dana‐Adriana Botesteanu, Seth M. Steinberg, Lori M. Minasian, Irene Ekwede, Elise C. Kohn - The Lancet 2018 cited by 212